2013 Nobel Prize Announcements

Södertälje-based Anocca has dosed the first patient in Sweden with its TCR-T cell therapy, which targets KRAS G12V mutations in pancreatic cancer. Sweden is the third European country where a patient has received the therapy.

LEO Pharma is acquiring worldwide rights to dersimelagon from Japan’s Tanabe Pharma in a deal worth up to USD 435 million, strengthening the Danish company’s rare dermatology pipeline.

EQL has recruited Oskar Karmlid as its new Chief Supply Chain Officer (CSCO).

The newly formed European Life Sciences Coalition (ELSC) has sent an open letter to leading decision-makers and politicians in the EU and Sweden, urging them to take action.

The board of directors of Cantargia has announced the outcome of the rights issue of shares that was announced on 28 May 2026.

The US‑based company has debuted in combined seed and Series A financing to advance a portfolio of mid‑stage neurology and neuropsychiatry drugs in‑licensed from Eisai and Hansoh.

BioArctic’s partner Eisai has announced that Leqembi (lecanemab), has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.